Basic catapres Information

• INN (International Nonproprietary Name): Clonidine
• Brand Names Available In United States: Catapres (tablets), Catapres-TTS (transdermal patches), Duraclon (injection for epidural use), Kapvay (extended‑release tablets for ADHD), Nexiclon XR (extended‑release tablets), Onyda XR (extended‑release suspension).
• ATC Code: C02AC01
• Forms & Dosages: Tablets 0.1 mg, 0.2 mg, 0.3 mg; Extended‑release tablets 0.1 mg and 0.17 mg; Transdermal patches 0.1–0.3 mg/24 hr equivalent; Injection 100 mcg/mL (Duraclon).
• Manufacturers In United States: Boehringer Ingelheim (Catapres), with generics supplied by Amneal, Accord, and other major manufacturers such as Mylan, Teva, and Sandoz supplying broader markets.
• Registration Status In United States: FDA approved for essential hypertension and for pediatric ADHD when using Kapvay extended‑release tablets; labeled approvals date back to 1974 for hypertension with Kapvay approval for ADHD per product labeling.
• OTC / Rx Classification: Prescription‑only (Rx) in the United States.

Key Findings From Recent Trials

What do clinicians and parents need to know from the 2022–2026 evidence on clonidine?

Major 2022–2026 Studies

Recent clinical and real‑world analyses revisited transdermal, extended‑release, and specialist injectable uses of clonidine across small randomized trials and cohort studies.

Trials examined Catapres‑TTS patches for blood pressure smoothing, Kapvay and Nexiclon XR ER tablets in pediatric ADHD, and epidural Duraclon in perioperative and cancer‑pain settings.

Study sizes were often modest, including crossover designs and specialist center cohorts, rather than large multicenter outcome trials.

Main Outcomes

Extended‑release clonidine formulations showed improved adherence compared with immediate‑release tablets in several analyses.

ER products were associated with fewer reports of daytime sedation when dosed at night, improving daytime functioning in many pediatric ADHD cohorts.

Transdermal Catapres‑TTS patches reduced 24‑hour blood pressure variability in small randomized or crossover trials compared with immediate‑release tablets, producing smoother overnight control.

Efficacy for off‑label indications such as withdrawal syndromes and migraine prevention remained mixed and mostly limited to specialist series rather than broad randomized evidence.

Safety Observations

Across studies, the safety profile matched historical labeling: rebound hypertension with abrupt discontinuation, bradycardia, orthostatic hypotension, and prolonged elimination in renal impairment.

Patch users sometimes reported contact dermatitis at application sites, while injection/epidural usage required specialist monitoring for cardiorespiratory effects.

Pharmacokinetic reports highlighted extended half‑life in severe renal impairment—values up to about 41 hours—supporting dose reduction strategies in that population.

Clinical Mechanism Of Action

How does clonidine work in plain language and in pharmacology terms?

Layman’s Explanation

Clonidine tells the brain to “turn down” sympathetic nerve signals that tighten blood vessels and raise heart rate.

That lowers blood pressure and produces a calming effect on the nervous system that can reduce hyperactivity and improve attention in some children with ADHD.

Scientific Breakdown

Clonidine is primarily an alpha‑2 adrenergic receptor agonist with activity at imidazoline receptors (ATC C02AC01).

Activation of presynaptic alpha‑2 receptors in the locus coeruleus and vasomotor centers reduces norepinephrine release and overall sympathetic tone.

Reduced sympathetic outflow lowers peripheral vascular resistance and heart rate, producing antihypertensive effects and central sedation that contribute to ADHD symptom control in select patients.

Receptor Targets & Pharmacology

The drug shows high affinity for alpha‑2A receptor subtypes, which are implicated in attention and sedation mechanisms relevant to ADHD and central nervous system effects.

Peripheral alpha‑2 effects reduce sympathetic activity and vascular tone.

Imidazoline receptor engagement provides additional central modulation of tonic sympathetic drive.

Clinically, these receptor activities explain dose‑dependent sedation, bradycardia risk, and the need for slow titration and tapering to avoid withdrawal effects.

Scope Of Approved And Off‑Label Use

Who is clonidine approved for, and what are common off‑label practices clinicians follow?

United States Approvals

FDA labeling lists clonidine tablets and transdermal systems for essential hypertension.

Extended‑release Kapvay is FDA‑approved for ADHD in children aged six years and older when clinically indicated.

Formulations in clinical use include immediate‑release tablets, clonidine ER (Kapvay, Nexiclon XR), Catapres‑TTS patches, and Duraclon injection for specialist procedures.

Notable Off‑Label Trends

Specialists commonly use clonidine in opioid or benzodiazepine tapering protocols to reduce sympathetic overactivity during withdrawal.

Perioperative hemodynamic control and epidural clonidine (Duraclon) for severe cancer pain are practiced in hospital settings under specialist supervision.

Investigational or limited‑evidence uses include migraine prevention and treatment of vasomotor symptoms, but evidence is heterogeneous and often restricted to small cohorts.

Dosage Strategy

What starting doses and titration steps are standard, and how do they change by condition?

General Dosing

For adult hypertension, a common starting oral regimen is 0.1 mg twice daily with stepwise titration as tolerated.

Typical formularies note maximum daily exposures in some regimens up to about 2.4 mg per day, although individual therapy varies widely.

ER tablets and transdermal patches alter frequency and timing considerations—ER and patch options are often favored to improve adherence.

Condition‑Specific Dosing

Hypertension: Start 0.1 mg orally twice daily and titrate upward under monitoring.

ADHD (Kapvay ER): Start 0.1 mg at bedtime and increase by 0.1 mg weekly as needed, with common pediatric maximum around 0.4 mg per day for children six years and older.

Transdermal Catapres‑TTS: Patches deliver steady 0.1–0.3 mg per 24 hours and are changed per product instructions for continuous coverage.

Duraclon Injection: 100 mcg/mL solution for epidural use in specialist hands only.

Dose Adjustments (Renal/Elderly/Children)

Children: Use ER formulations only for ADHD patients aged six and older; bedtime initiation reduces daytime sedation risk.

Elderly: Start at the lower end of dosing ranges and monitor carefully for orthostatic hypotension and bradycardia.

Renal Impairment: Reduce dose and slow titration because elimination half‑life can be prolonged (up to ~41 hours), increasing accumulation risk.

Safety Protocols

What are absolute contraindications, common adverse effects, and monitoring essentials?

Contraindications

Absolute contraindications include known hypersensitivity to clonidine or any component of the formulation.

Severe bradyarrhythmias such as second‑ or third‑degree AV block without a pacemaker are contraindications.

Use caution or avoid in recent myocardial infarction and severe coronary insufficiency unless under close cardiology supervision.

Adverse Effects

Common mild effects are dry mouth, drowsiness, headache, constipation, and dizziness.

More significant risks include symptomatic bradycardia, orthostatic hypotension, and rebound hypertension on abrupt cessation.

Patch users can develop localized skin reactions or contact dermatitis at application sites.

Monitoring Essentials

Obtain baseline blood pressure and heart rate and perform orthostatic checks during early titration.

Screen for mood changes or worsening depression prior to and during use, particularly in patients with psychiatric history.

Monitor renal function periodically to guide dose adjustments when impairment is present.

For epidural or injectable Duraclon, continuous cardiorespiratory monitoring is required in the hospital setting.

Always counsel patients and caregivers not to stop clonidine abruptly and provide a taper plan to avoid hypertensive crisis.

Interaction Mapping

Which foods and medications change safety or effectiveness, and how should clinicians manage interactions?

Food Interactions

No major food‑drug binding interactions appear in core labeling.

Alcohol and other sedating substances can potentiate CNS depression, so patients should be warned to avoid alcohol until tolerance is known.

Transdermal patches are sensitive to topical heat—heat application can increase absorption and should be avoided.

Drug Combinations To Avoid

Concomitant CNS depressants such as benzodiazepines, opioids, and sedating antihistamines increase sedation and respiratory depression risk.

Tricyclic antidepressants can blunt clonidine’s antihypertensive effect and complicate withdrawal dynamics if altered.

Combining clonidine with beta‑blockers may accentuate bradycardia; adding other antihypertensives increases orthostatic hypotension risk.

Interaction Management Strategies

Review medication lists carefully for CNS depressants and tricyclic agents before initiating clonidine.

When stopping clonidine, plan gradual tapers, especially if patients are on other sympathetic‑modulating drugs.

Monitor vitals closely when adding or removing interacting agents and counsel patients about alcohol and over‑the‑counter sleep aids.

Patient Experience Analysis

What do real patients and parents say about clonidine treatment in daily life?

Survey Data

Clinic cohorts and pharmacovigilance data report that dry mouth and transient drowsiness are common early after initiation.

Many patients note symptom improvement over time or after switching to an ER formulation or a transdermal patch.

Adherence measures improve when patients switch from multiple daily immediate‑release doses to once‑daily ER tablets or a 24‑hour patch.

Forum Trends

Online forums and parent groups often praise patch convenience for steady control, while also flagging skin irritation as a downside.

Parents using Kapvay for ADHD frequently describe bedtime dosing as helpful for controlling nighttime hyperactivity, with daytime fatigue during initial titration being a reported concern.

Stories about abrupt discontinuation causing rebound hypertension and anxiety appear repeatedly and support counseling on tapering.

A practical patient preference is a regimen that minimizes daytime sedation—ER bedtime dosing or patches are commonly chosen for that reason.

Distribution And Pricing Landscape

How widely available is clonidine and what affects cost and access?

Manufacturers & Supply Chains

Boehringer Ingelheim markets Catapres and Catapres‑TTS, while multiple manufacturers supply generics and ER products.

Major generic suppliers in the US include Amneal and Accord, with larger multinational suppliers such as Mylan, Teva, and Sandoz contributing to supply stability.

Injectable Duraclon is normally stocked through hospital procurement channels for specialist use.

Packaging & Access

Catapres tablets are typically supplied in blister packs in cartons of 30 or 60 tablets; Catapres‑TTS patches come sealed in foil pouches.

Generics reduce unit cost substantially compared with branded ER products like Kapvay and Nexiclon XR, which remain priced higher due to specific pediatric labeling.

Insurance formularies and prior‑authorization rules often determine whether patients receive generic clonidine, Kapvay ER, or transdermal patch formulations.

In our online pharmacy, catapres is available without a prescription, with discreet delivery to United States in 5‑14 days.

Alternative Options

Which drugs are chosen instead of clonidine, and what are the tradeoffs?

Comparison Overview

Alternatives for central sympathetic modulation include methyldopa and guanfacine, while first‑line antihypertensives for most patients are ACE inhibitors, ARBs, and calcium channel blockers.

For ADHD, stimulant medications and nonstimulants such as atomoxetine and guanfacine ER are commonly used instead of clonidine ER.

Pros And Cons

Methyldopa: Pros—well established safety in pregnancy; Cons—sedation and potential hepatic concerns.

Guanfacine ER: Pros—similar alpha‑2 mechanism with possibly less hypotension; Cons—different efficacy profile and variable sleep effects compared with clonidine ER.

ACE inhibitors/ARBs/CCBs: Pros—proven cardiovascular outcome benefits and first‑line status; Cons—do not provide central sympathetic modulation or ADHD symptom control.

Stimulants for ADHD: Pros—greater efficacy for core symptoms in many children; Cons—potential abuse risk and insomnia concerns, making nonstimulants like Kapvay an important option for some families.

Regulatory Status

What is the global and US regulatory picture for clonidine?

Global Approvals Snapshot

Clonidine is registered worldwide as a prescription medicine under various brand names and generics.

In the US, FDA approvals cover essential hypertension and pediatric ADHD for Kapvay extended‑release tablets.

European and national authorities list generic clonidine and branded Catapres under their respective marketing authorizations.

Prescription & Labeling Notes

Generally Rx‑only status applies in most jurisdictions, and labeling differences reflect specific indications for each formulation—Kapvay ER for ADHD versus Catapres tablets/patches for hypertension.

Label guidance emphasizes tapering to avoid rebound hypertension and special population dosing adjustments for renal impairment and the elderly.

Pharmacovigilance continues to monitor rebound hypertensive events, sedation incidents, and patch site reactions.

Consolidated FAQ

Quick answers clinicians and patients commonly need about clonidine and Catapres.

Quick Answers Clinicians/Patients Need

Q: Is Catapres the same as clonidine?

A: Catapres is a brand name for clonidine; multiple generic versions also exist.

Q: Can I stop clonidine abruptly?

A: No—abrupt discontinuation risks rebound hypertension; taper under clinician guidance.

Q: Which formulations exist?

A: Tablets 0.1–0.3 mg, ER tablets (Kapvay 0.1 mg; Nexiclon XR 0.1/0.17 mg), Catapres‑TTS patches 0.1–0.3 mg/24 hr, and Duraclon injection 100 mcg/mL.

Q: How should clonidine be stored?

A: Store tablets at room temperature (20–25°C), protect from light and moisture; keep patches in original sealed pouches.

Q: What are the key safety flags?

A: Hypersensitivity, severe bradyarrhythmias, pregnancy considerations, and renal impairment requiring dose reduction and monitoring.

Q: What about pediatric use?

A: Kapvay ER is FDA‑approved for children age six and older for ADHD; immediate‑release tablets are not first‑line in pediatric patients.

Visual Guide

Which diagrams and icons help readers understand clonidine quickly?

Suggested Diagrams & Figures

Include an MOA infographic showing central alpha‑2 receptor action and imidazoline involvement with simplified neural circuit arrows.

Supply a dosing ladder image comparing immediate‑release dosing with ER tablets, patch equivalents, and injection options showing typical starting doses and titration steps.

Add a safety flowchart for initiation and tapering with vitals checks and triggers for dose reduction.

Provide a patch placement diagram with skin care tips and a quick reference table mapping formulations to brand names (Catapres, Kapvay, Nexiclon XR, Duraclon, Clonidina).

Iconography & Labeling Tips

Use simple icons for “Rx‑only,” “Do Not Stop Abruptly,” and “Renal Dose Caution.”

Also include storage icons for room temperature and sealed pouch for patches and cite product labeling where possible to support claims.

Storage And Transport

How should pharmacies and patients handle and store clonidine products?

Product Storage Guidance

Tablets should be stored at controlled room temperature, approximately 20–25°C, protected from light and moisture.

Transdermal patches must remain in their original sealed foil pouches until use and be kept away from extreme heat that can increase absorption.

Injectable Duraclon should be managed under hospital sterility and cold‑chain policies where applicable and must not be frozen unless specified by institutional protocols.

Distribution Handling Notes

Ship patches using temperature‑stable packaging and avoid prolonged exposure to high temperatures in transport.

Community pharmacies should keep blister packs and cartons for batch traceability and expiry monitoring.

Advise patients to discard used patches safely and to keep tablets in original containers with clear labeling.

Guidelines For Proper Use

What practical steps ensure safe initiation, monitoring, and stopping of clonidine?

Titration & Tapering

Start low and titrate slowly to reduce early sedation and orthostatic risks—adults often begin at 0.1 mg twice daily, while Kapvay ER typically starts at 0.1 mg at bedtime with weekly 0.1 mg increments in children.

Always prepare a taper schedule for discontinuation; abrupt stopping risks rebound hypertension and sympathetic overactivity.

Monitoring & Follow‑Up

Perform baseline BP and HR and repeat orthostatic vitals during early titration.

Check renal function periodically to guide dose adjustments in impaired patients.

Assess mood and screen for depressive symptoms, and for ER or patch users evaluate daytime somnolence and skin integrity on follow‑up visits.

Provide patients clear missed‑dose guidance: take as soon as remembered unless close to the next dose; do not double doses.

Teach emergency signs of overdose such as severe hypotension or profound somnolence that require urgent care.

Delivery Across United States